ReviewDialogues in health2026
Impact of COVID-19 on TB and HIV/AIDS severity in low- and middle-income countries: a systematic review.
Review in Dialogues in health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Beyond its profound health, social, and economic consequences, COVID-19 poses a serious threat to the management of tuberculosis (TB) and HIV/AIDS. However, empirical evidence remains limited. This study evaluates the impact of the COVID-19 pandemic on TB and HIV/AIDS service delivery across low- and middle-income countries. Methods: This systematic review protocol was registered with PROSPERO (CRD42021266242). Following PRISMA guidelines, we searched databases-including PubMed, ClinicalTrials.gov, and CINAHL-for studies on TB and HIV/AIDS services published between January 1, 2019, and January 8, 2024. A random-effects model calculated pooled relative risks to evaluate overall TB/HIV outcome severity, and subgroup analyses were performed to evaluate regional risk variations. Results: In low- and middle-income countries, non-TB patients with COVID-19 had a lower risk of severe outcomes compared to those with TB (pooled OR = 0.71, 95% CI: 0.60-0.83). Conversely, HIV patients with COVID-19 faced an increased risk of severe disease (pooled RR = 1.78, 95% CI: 1.45-2.19). By region, the pooled OR for severe COVID-19 in patients with TB was 0.83 (95% CI: 0.63-1.08) in Asia and 0.64 (95% CI: 0.51-0.79) in Africa. For HIV patients with COVID-19, the risk of severe disease was 1.73 (95% CI: 1.38-2.18) in Asia and 1.98 (95% CI: 1.26-3.10) in Africa. Conclusion: In low- and middle-income countries, COVID-19 patients with underlying conditions were significantly more likely to experience severe outcomes than those without comorbidities. Furthermore, the pandemic severely disrupted fragile health systems in these regions, exacerbating the burden of tuberculosis and HIV/AIDS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.